Catalog No.
DHB86903
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG2-kappa
Clonality
Monoclonal
Target
HER1, Receptor tyrosine-protein kinase erbB-1, Proto-oncogene c-ErbB-1, Epidermal growth factor receptor, EGFR, ERBB1, ERBB
Concentration
8.58 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P00533
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
ABX-EGF, E7.6.3, CAS: 339177-26-3
Clone ID
Panitumumab
Panitumumab, PMID: 17171190
Different Toxicity of Cetuximab and Panitumumab in Metastatic Colorectal Cancer Treatment: A Systematic Review and Meta-Analysis, PMID: 29393280
FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109), PMID: 31609637
Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G), PMID: 32526634
Metastatic colorectal cancer: treatment with panitumumab, PMID: 30365654
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer, PMID: 18316791
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study, PMID: 24739896
Panitumumab in the treatment of metastatic colorectal cancer, including wild-type RAS, KRAS and NRAS mCRC, PMID: 29737864
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis, PMID: 33336844
Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy, PMID: 31539295
Panitumumab-induced pulmonary toxicity, PMID: 31708664
Trichomegaly Associated with Panitumumab, PMID: 33053288
Panitumumab, PMID: 19843050
Panitumumab, PMID: 17201026
Panitumumab in metastatic colorectal cancer, PMID: 23802848
Panitumumab safety for treating colorectal cancer, PMID: 24766434
Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma, PMID: 28424871
Panitumumab for the treatment of metastatic colorectal cancer: a review, PMID: 26250414
Panitumumab: in the treatment of metastatic colorectal cancer, PMID: 17100412
Panitumumab (vectibix), PMID: 21596817
Panitumumab in combination with cytotoxic chemotherapy for the treatment of metastatic colorectal carcinoma, PMID: 21925954
Panitumumab: in metastatic colorectal cancer with wild-type KRAS, PMID: 18998757
Panitumumab in the treatment of colon cancer: A biomarker dilemma, PMID: 25374966
The efficacy of panitumumab in refractory metastatic colorectal cancer: A meta-analysis, PMID: 31646791
Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review, PMID: 29183279
Panitumumab-IRDye800CW for Fluorescence-Guided Surgical Resection of Colorectal Cancer, PMID: 30798171
Comparison of Panitumumab-IRDye800CW and 5-Aminolevulinic Acid to Provide Optical Contrast in a Model of Glioblastoma Multiforme, PMID: 32606015
Panitumumab the first fully human monoclonal antibody: from the bench to the clinic, PMID: 17159497
Panitumumab: a summary of clinical development in colorectal cancer and future directions, PMID: 22515440
Spotlight on panitumumab in metastatic colorectal cancer, PMID: 20623992
Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis, PMID: 30499082
Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer, PMID: 17355997
Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer, PMID: 18343240
Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status, PMID: 25895463
Panitumumab : leading to better overall survival in metastatic colorectal cancer?, PMID: 24593265
Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to 111 In and 177 Lu-An EGFR-Targeted Theranostic for Pancreatic Cancer, PMID: 29314858
Panitumumab: A Review of Clinical Pharmacokinetic and Pharmacology Properties After Over a Decade of Experience in Patients with Solid Tumors, PMID: 34152568
Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials, PMID: 30614531
Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer, PMID: 33469991
Role of panitumumab in the management of metastatic colorectal cancer, PMID: 16945167
Panitumumab in colon cancer: a review and summary of ongoing trials, PMID: 17049019
Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer, PMID: 28853050
KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician, PMID: 31553708
Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab, PMID: 20923247
The efficacy and safety of panitumumab supplementation for colorectal cancer: A meta-analysis of randomized controlled studies, PMID: 32176047
Panitumumab-Conjugated and Platinum-Cored pH-Sensitive Apoferritin Nanocages for Colorectal Cancer-Targeted Therapy, PMID: 29368506
Panitumumab - an effective long-term treatment for patients with metastatic colorectal cancer and wild-type KRAS status, PMID: 20189055
Phase II Study of Panitumumab Monotherapy in Chemotherapy-Naïve Frail or Elderly Patients with Unresectable RAS Wild-Type Colorectal Cancer: OGSG 1602, PMID: 32918848
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer, PMID: 29431699
Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer, PMID: 31902066
For research use only. Not for human or drug use.
